CorMedix Inc.: management transactions · United States · SEC (Form 4)

About CorMedix Inc.

CorMedix Inc. is a US-based biopharmaceutical company listed on the NASDAQ in the United States. Over the past several years, the company has evolved from a narrowly focused developer into a broader commercial specialty-pharma platform centered on acute-care injectable products and hospital-adjacent infectious disease therapies. CorMedix was originally formed under the name Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in 2007. Its corporate footprint is concentrated in New Jersey, with headquarters now associated with Parsippany and additional operational presence in Berkeley Heights. ([stockanalysis.com](https://stockanalysis.com/stocks/crmd/company/?utm_source=openai)) The company’s core commercial story is built around DefenCath, a taurolidine-and-heparin catheter lock solution designed to reduce catheter-related bloodstream infections in hemodialysis patients. DefenCath received FDA approval in November 2023 and was launched in the United States in 2024, first in the inpatient setting and later in the outpatient setting. Management has stated that its contracted dialysis customer base covers a meaningful share of the US outpatient dialysis-center market, which gives CorMedix a real, albeit still specialized, commercial platform rather than a purely development-stage profile. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/ea0278169-10k_cormedix.htm)) A major strategic inflection point came in 2025 with the acquisition of Melinta Therapeutics, completed on August 29, 2025. That transaction materially broadened the product set beyond DefenCath, adding a portfolio of anti-infectives and related commercial assets, plus contract and royalty revenue streams. CorMedix now describes itself as a diversified specialty injectables company with eight products in its current portfolio, including DefenCath, six anti-infectives, and a mature branded product. The company’s commercial positioning is centered on hospitals, integrated delivery networks, physician offices, infusion centers, home infusion, and long-term acute-care facilities. ([cormedix.com](https://cormedix.com/wp-content/uploads/2025/09/CorMedix_Corporate-Presentation_9-19-25.pdf)) From a competitive standpoint, CorMedix remains smaller than the major multinational pharmaceutical groups, but it has carved out a niche in high-acuity anti-infective care where clinical differentiation and channel access matter. Its strategic edge lies in combining an approved flagship asset with a broader portfolio that can be sold through overlapping acute-care call points. The company also highlights label-expansion opportunities and pipeline programs, including studies aimed at expanding DefenCath and REZZAYO into larger addressable markets. ([cormedix.com](https://cormedix.com/wp-content/uploads/2025/09/CorMedix_Corporate-Presentation_9-19-25.pdf)) Recent developments underscore the improved scale of the business. In its 2025 annual report, CorMedix reported total revenue of $311.7 million and net income of $163.1 million, driven primarily by product sales of DefenCath and supplemented by the acquired Melinta portfolio. The company also reported that it achieved profitability in 2025 and continued to assess additional growth initiatives, integration benefits, and clinical-expansion opportunities in 2026. For investors, CRMD represents a NASDAQ-listed US healthcare company with a commercial product, a broadened specialty portfolio, and a strategic growth plan still in execution. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1410098/000121390026023889/ea0278169-10k_cormedix.htm))